...
首页> 外文期刊>Vaccine >Influence of clinical outcome and outcome period definitions on estimates of absolute clinical and economic benefits of influenza vaccination in community dwelling elderly persons
【24h】

Influence of clinical outcome and outcome period definitions on estimates of absolute clinical and economic benefits of influenza vaccination in community dwelling elderly persons

机译:临床结果和结果期限定义对社区居住的老年人中流感疫苗接种的绝对临床和经济效益估算的影响

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Studies assessing the clinical and economic benefits of vaccination in the elderly have used different clinical outcomes (e.g. hospitalizations for pneumonia or influenza versus hospitalizations for respiratory and cardiovascular causes) and different outcome periods (e.g. peak versus total influenza season) on which to base estimates of clinical effectiveness and cost effectiveness. We explored the implications of these varying approaches by comparing two health economic analysis models of influenza vaccination of community-dwelling elderly persons. We developed computerized models using clinical data from 3 large US HMOs for the 1998-1999 and 1999-2000 influenza seasons. The primary health economic model used a broad definition of clinical events and outcome period and included hospitalizations for all respiratory and cardiovascular events that occurred during the entire influenza season. The alternative model used more restrictive definitions and included pneumonia or influenza hospitalizations occurring during the peak influenza season. The results of Monte Carlo simulation showed that, with the more inclusive primary model, influenza vaccination resulted in net medical care cost savings due to fewer respiratory or cardiovascular hospitalizations of Dollars 71/person vaccinated (5th-95th percentile Dollars 32-118) and net savings of Dollars 809/year of life saved (5th-95th percentile Dollars 331-1450). In contrast, the alternate model found costs of Dollars 3.50/person vaccinated (5th-95th percentile Dollars -11 to 5) and net costs of Dollars 91/year of life saved (5th-95th percentile Dollars -309 to 126). Our findings confirm that influenza vaccination of the elderly is most likely cost saving and supports policies and programs that advocate routine immunization of all persons 65 and older. They also highlight how different outcome definitions can influence the results of health economic analyses.
机译:评估老年人接种疫苗的临床和经济效益的研究使用了不同的临床结局(例如,因肺炎或流感住院,而因呼吸系统和心血管原因而住院)和不同的结局时期(例如高峰期与总流感季节)作为估计的基础临床效果和成本效益。我们通过比较社区居民老年人接种流感疫苗的两种健康经济分析模型,探索了这些不同方法的含义。我们使用来自3个大型美国HMO的1998-1999年和1999-2000年流感季节的临床数据开发了计算机模型。初级卫生经济模型对临床事件和预后期进行了广泛定义,并包括了整个流感季节期间发生的所有呼吸道和心血管事件的住院治疗。替代模型使用了更严格的定义,包括在流感高峰季节发生的肺炎或流感住院。蒙特卡洛模拟的结果表明,采用更具包容性的基本模型,由于接种疫苗的人均获得的美元或每人接种的美元71元(第5至95%,32-118美元)较少,呼吸道或心血管疾病住院费用减少,因此流感疫苗接种净节省了医疗费用每年可节省809美元(每5到95%的美元331-1450)。相比之下,替代模型发现接种疫苗的人均费用为3.50美元(5-95%-11至5美元)和每节省生命年的费用为91美元(5-95%-309至126美元)。我们的研究结果证实,老年人流感疫苗接种最有可能节省成本,并支持提倡对65岁及65岁以上所有人进行常规免疫的政策和计划。他们还强调了不同的结果定义如何影响卫生经济分析的结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号